FIXX Share Price Performance
US$0
0.00 (0.00%)
Price US$0
Share Pricen/a
Homology Medicines, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
FIXX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Homology Medicines, Inc. Key Details
Last Reported Earnings
Dec 31, 2023
Next Reporting Earnings
n/a
- -34.98
- -5,263.49%
- -9,771.71%
- 0%
About FIXX
- Founded
- 2015
- Employees
- 7
- CEO
- WebsiteView website
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
